[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

615A.O1.6 615. Acute Myeloid Leukemia - Therapy, excluding Transplantation: Randomized Trials

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 12, 2011: 7:00 AM-8:30 AM
Room 30 (San Diego Convention Center)
Moderators:
Peter G. Maslak, M.D., Memorial Sloan-Kettering Cancer Center and Rebecca L. Olin, MD, MS, UCSF

Disclosures:
No relevant conflicts of interest to declare.
7:00 AM
Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA)

Clémentine Sarkozy1,2, Claude Gardin, MD3*, Nathalie Gachard4*, Fatiha Merabet2*, Pascal Turlure4*, Jean-Valère Malfuson5*, Cécile Pautas6*, Jean-Baptiste Micol1*, Xavier Thomas, MD, PhD7*, Bruno Quesnel8, Karine Celli-Lebras1*, Claude Preudhomme9*, Christine Terré2*, Sylvie Chevret10*, Mauricette Michallet7, Catherine Cordonnier6, Pierre Fenaux, MD, PhD3, Dominique Bordessoule11, Sylvie Castaigne2 and Hervé Dombret1

1Hôpital Saint-Louis, AP-HP, Université Paris 7, EA 3518, Paris, France
2Hôpital de Versailles, Université Versailles - Saint Quentin , Le Chesnay, France
3Hôpital Avicenne, AP-HP, Université Paris 13, Bobigny, France
4CHU Dupuytren, Université Limoges, Limoges, France
5Hôpital Percy, Clamart, France
6Hôpital Henri Mondor, AP-HP, Université Paris 12, Créteil, France
7Hôpital Edouard Herriot, HCL, Université Lyon 1, Lyon, France
8CHRU de Lille, Université Lille, Lille, France
9CHRU Lille, Université Lille, Lille, France
10Biostatistics, Hôpital Saint-Louis, AP-HP, Université Paris 7, Paris, France
11Hématologie Clinique et Thérapie Cellulaire, CHU Limoges, Limoges, France

7:15 AM
CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in ≤65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report

Jorge E. Cortes, MD1, Eric J Feldman, MD2, Stuart L. Goldberg, MD3, David A. Rizzieri, MD4, Kim H. Paulsen5*, Arthur C. Louie, MD6 and Jonathan E. Kolitz, MD7

1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY
3Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
4Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC
5Celator Pharmaceuticals, Inc., Princeton, NJ
6Celator Pharmaceuticals, Princeton, NJ
7Department of Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY

7:30 AM
No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Stefani Parmentier, MD1*, Martin Bornhäuser, MD, Prof.2*, Christian Thiede, MD2, Christoph Röllig, MD2*, Michael Kramer2*, Mathias Haenel, MD3*, Regina Herbst, MD4*, Norbert Schmitz, MD, Prof.5, Reingard Stuhlmann, MD5*, Hannes Wandt6*, Kerstin Schäfer-Eckart, MD7*, Walter E. Aulitzky8, Martin Kaufmann, MD8*, Anthony D. Ho9, Alwin Krämer, MD9*, Wolfgang E. Berdel10, Carsten Müller-Tidow, MD10*, Hubert Serve, MD11, Gerhard Ehninger, MD2 and Markus Schaich, MD2*

1Medical Department I, University Hospital Carl Gustav Carus Dresden, Dresden, Germany
2Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
3Medizinische Klinik III, Klinikum Chemnitz gGmbH, Chemnitz, Germany
4Klinik für Innere Medizin III, Klinikum Chemnitz gGmbH, Chemnitz, Germany
5Abt. Hämatologie und Stammzelltransplantation, ASKLEPIOS Klinik St. Georg, Hamburg, Germany
65. Medizinische Klinik, Klinikum Nürnberg, Nürnberg, Germany
75. Medizinische Klinik , Klinikum Nürnberg, Nürnberg, Germany
8Robert-Bosch-Krankenhaus, Stuttgart, Germany
9University Hospital Heidelberg, Heidelberg, Germany
10Medicine A - Hematology / Oncology and Pneumology, University of Muenster, Muenster, Germany
11Department of Medicine, Hematology/Oncology, Goethe-University Frankfurt, Frankfurt, Germany

7:45 AM
Efficacy of Cladribine, Cytarabine, G-CSF (Neupogen), Mitoxantrone (CLAG-M Regimen) Compared to Standard 3+7 (Anthracycline and Cytarabine) in Secondary Acute Myeloid Leukemia (sAML) After Azanucleosides Failure

Michael V. Jaglal, MD1, Vu H. Duong, MD1, Celeste M. Bello, MD2, Najla H Al Ali, M.S3*, Hugo F. Fernandez, MD4, Jeffrey E. Lancet, MD3, Alan F. List, MD1 and Rami S. Komrokji, MD5

1Moffitt Cancer Center, Tampa, FL
2Department of Malignant Hematology,, H. Lee Moffitt Cancer Center, Tampa, FL
3Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
4Blood and Bone Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Instittute, Tampa, FL
5Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL

8:00 AM
High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC  

Roelof Willemze, MD, PhD1, Stefan Suciu2, Franco Mandelli, MD3*, Giovanna Meloni4*, Boris Labar5, Stijn J.M. Halkes1, Petra Muus, MD, PhD6, Martin Mistrik, MD, PhD7, Giorgina Specchia8, Francesco Fabbiano, MD9, Francesco Nobile, MD10*, Marco Sborgia11*, Andrea Camera12*, Dominik Selleslag13*, Francois Lefrere14*, Domenico Magro, MD15*, Giuseppe Leone16, Nicola Cantore17*, Meral Beksac, MD18, Zwi Berneman19, Xavier Thomas20*, Lorella Melillo21*, Dominique Bron22, Georges Fillet23, Jose E. Guimaraes, MD, PhD24, Sergio Amadori25, Paola Fazi4*, Matthias Karrasch26*, Marco Vignetti27*, Theo de Witte28* and Jean-Pierre Marie, MD29

1Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
2EORTC Headquarters, Brussels, Belgium
3Universita 'La Sapienza', Rome, Italy
4Hematology, Sapienza University, Rome, Italy
5University Hospital Center Rebro, Zagreb, Croatia
6Department of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
7Department of Hematology , Comenius University , Bratislava, Slovakia
8University of Bari, Hematology, Bari, Italy
9Hematology, Ospedali Riuniti , Palermo, Italy
10Ospedale Bianchi-Melacrino-Morelli, Hematology, Reggio Calabria, Italy
11Hematology, U.O.di Ematologia Clinica, Pescara, Italy
12Hematology, A.O.Universitaria, Napoli, Italy
13AZ St. Jan, Brugge, Belgium
14Hematology, Hopital Necker , Paris, France
15Hematology, Catanzaro
16Department of Hematology, Università Cattolica, Rome, Italy
17Division of Hematology, Avellino, Italy
18Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
19UZA, Antwerpen, Belgium
20Hôpital Edouard Herriot, HCL, Université Lyon 1, Lyon, France
21Hematology, , Ospedale Casa Sollievo della Sofferenza, Italy
22Dept. of Experimental Hem., Jules Bordet Institute, Brussels, Belgium
23ULg, Liege, Belgium
24Serviço de Hematologia Clínica, Hospital S. João, Porto, Portugal
25Department of Hematology, University Tor Vergata, Rome, Italy
26Medical Department, European Organization for Research and Treatment of Cancer, Brussels, Belgium
27hematology, Gimema foundation, rome, Italy
28hematology, Radboud University Nijmegen Medical Center, nijmegen, Netherlands
29Hematologie et Oncologie Medicale, Hopital Hotel-Dieu, Paris, France

8:15 AM
Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission:  Results From North American Leukemia Intergroup Trial C9710Clinically Relevant Abstract

Bayard L. Powell, MD1, Barry K Moser, Ph.D.2*, Wendy Stock, MD3, Robert E. Gallagher, MD4, Cheryl L Willman, MD5, Richard M. Stone, MD6, Jacob M. Rowe, MD7, Steven E. Coutre, MD8, James H. Feusner, M.D.9*, John Gregory, MD10, Stephen Couban, MD, FRCPC11, Frederick R. Appelbaum, MD12, Martin S. Tallman, MD13 and Richard A. Larson, MD14

1Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC
2CALGB Statistical Center, Duke University, Durham, NC
3University of Chicago, Hematology/Oncology and Comprehensive Cancer Center, Chicago, IL
4Albert Einstein College of Medicine, Bronx, NY
5University of New Mexico Cancer Center, Albuquerque, NM
6Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
7Rambam Medical Center, Technion, Haifa, Israel
8Divisions of Hematology and Oncology and Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA
9Children's Hospital and Research Center, Oakland, CA
10Atlantic Health System, Goryeb Children's Hospital, Morristown, NJ
11Hematology, Dalhousie University, Halifax, NS, Canada
12Fred Hutchinson Cancer Research Center, Seattle, WA
13Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
14Hematology/Oncology and Comprehensive Cancer Center, University of Chicago, Chicago, IL

*signifies non-member of ASH